EN DE
Watch MEKICS Co Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

MEKICS Co Ltd (058110) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of MEKICS Co Ltd stock KRW 1,511, price KRW 1,360, upside +11.1%, quality 46 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7058110008

MC MEKICS Co Ltd logo Thin data Nov 16, 2026

MEKICS Co Ltd

058110 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value 1,511 KRW · Fairly valued 
Quality 46/100 
Thin margins · 3.2% net margin (TTM) 
Mixed vs. peers (4/10) 
Revenue last quarter 56% below a year ago. 
Falling price (downtrend) 
Weak Growth (revenue 5y −30.2 %/yr in KRW) 
Negative free cash flow 
Narrow moat 14/100
Thin data 
Estimate
Watch MEKICS Co Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

16,410 KRW 1,255 KRW Fair Value 1,511 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,255 KRW – 16,410 KRW · fair‑value band 1,133 KRW – 1,888 KRW · the 1,360 KRW price screens below the 1,511 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow MEKICS Co in your weekly email

Every Wednesday you see whether MEKICS Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MEKICS CO., Ltd develops and commercializes ventilators worldwide. It offers general-purpose ventilators, respiratory care devices, patient monitoring systems, pulse oximeter, central monitoring system, and high flow nasal therapy products.

Show moreShow less

The company also distributes CPAP solutions that care sleep apnea syndrome and snoring. MEKICS CO., Ltd was founded in 1998 and is headquartered in Paju, South Korea.

Stock analysis

MEKICS Co Ltd (058110) currently trades at 1,360 KRW, while our estimate is 1,511 KRW, so the stock looks roughly fairly valued today (gap 10.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,133 KRW (bear) to 1,888 KRW (bull), the price of 1,360 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

MEKICS Co Ltd reported revenue of 11.3B KRW in FY2025 versus 49.3B KRW in FY2021, a compound −30.8%/yr. Reported net income was −2.5B KRW in FY2025.

Key figures

Market cap 21.1B KRW (≈ $15.8M) Micro · P/S ratio 0.66 · Net margin 3.2% · Return on equity −2,189% · Return on assets (EBIT) −6.5% (5-year average) · Operating margin −2.8% · Revenue (TTM) 33.2B KRW · Revenue growth (YoY) −56.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (medium confidence).

What moves the price

The share trades about 61% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 11%, 058110 screens cheaper than that median.

Fair Value

Bear 1,133 KRW Fair Value 1,511 KRW Bull 1,888 KRW
Price 1,360 KRW · Upside +11.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.2%
Start year 2020 (pandemic). Over 10 years: +2.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
44.6% (2020) → −24.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 058110, get fair value alerts →

Compare MEKICS Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2778 stocks

Beats the sector median on 4/10 measures
A mixed picture versus its sector peers.
Valuation
Quality Score 46 · Below median
Fair Value upside +11.1% · Above median
Profitability
Return on assets −4.5% · Below median
Net margin (12 months) 3.2% · Below median
Operating margin (12 months) −2.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) −56.3% · Bottom 25%
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 0.58× · Cheapest 25%
P/S (12 months) 0.63× · Cheapest 25%
EV/EBITDA 11.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)48 · sector 14
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 8
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Value Added Technology Co 043150 17,040 KRW 48,636 KRW +185% vs 058110
Sewoon Medical Co 100700 2,145 KRW 5,541 KRW +158% vs 058110
Meta Biomed Co 059210 3,210 KRW 6,997 KRW +118% vs 058110
InBody Co 041830 40,000 KRW 49,984 KRW +25% vs 058110
AbbVie Inc ABBV $292.82 $259.62 −11% vs 058110
Roche Holding RO CHF 407.60 CHF 326.56 −20% vs 058110
Mediana Co 041920 7,120 KRW 5,424 KRW −24% vs 058110
Johnson & Johnson, JNJ $278.70 $169.03 −39% vs 058110
Eli Lilly and Company LLY $1,416 $749.92 −47% vs 058110
MEDIC MEDIC 0.2400 PHP 0.1000 PHP −58% vs 058110

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEKICS Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MEKICS Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/058110

Frequently asked questions

Is MEKICS Co Ltd (058110) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,511 KRW versus a price of 1,360 KRW, about +11% upside (fairly valued).
What is the fair value of 058110?
Our estimate for MEKICS Co Ltd is 1,511 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,360 KRW.
What is the quality score of 058110?
MEKICS Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEKICS Co Ltd (058110)?
Our calculated price target is the estimate of 1,511 KRW (as of Nov 16, 2026). Cautious scenario 1,133 KRW, optimistic scenario 1,888 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the MEKICS Co Ltd stock forecast for 2026?
Our estimate puts fair value at 1,511 KRW, about +11% upside versus a price of 1,360 KRW (fairly valued). Cautious scenario 1,133 KRW, optimistic scenario 1,888 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MEKICS Co Ltd (058110)?
MEKICS Co Ltd reported trailing-twelve-month revenue of about 33.2B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of MEKICS Co Ltd (058110)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEKICS Co Ltd it is 1,511 KRW per share (as of Nov 16, 2026), against a price of 1,360 KRW.
Is MEKICS Co Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 058110 trades below its calculated fair value: price 1,360 KRW, fair value 1,511 KRW, a gap of about +11% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 058110?
No. The price is what the market pays today (1,360 KRW); the fair value is what the company's own numbers justify (1,511 KRW). For MEKICS Co Ltd the two are 150.80 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MEKICS Co Ltd worth?
The market values MEKICS Co Ltd at about 21.1B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,360 KRW; our models calculate a fair value of 1,511 KRW per share.
What do the bullish and bearish scenarios say about 058110?
Our models span a range for MEKICS Co Ltd: cautious scenario 1,133 KRW, base 1,511 KRW, optimistic 1,888 KRW per share (as of Nov 16, 2026, price 1,360 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MEKICS Co Ltd (058110)?
Balance-sheet figures for MEKICS Co Ltd (as of Nov 16, 2026): debt of 0.11 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 058110 from its 52-week high?
MEKICS Co Ltd trades at 1,360 KRW, about 61% below its 52-week high of 3,460 KRW and 8% above the low of 1,255 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 1,511 KRW is for.
Which stocks are comparable to MEKICS Co Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Sewoon Medical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEKICS Co Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 1,360 KRW, calculated fair value 1,511 KRW (+11%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. MEKICS Co Ltd currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEKICS Co Ltd (058110)?
The closing price on Nov 18, 2026 was 1,360 KRW. Our estimate is 1,511 KRW, about +11% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEKICS Co Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of MEKICS Co Ltd

How large is the market capitalisation of MEKICS Co Ltd (058110)?
The market capitalisation of MEKICS Co Ltd is 21.1B KRW (≈ $15.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEKICS Co Ltd (058110)?
The price-to-sales ratio of MEKICS Co Ltd is 0.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of MEKICS Co Ltd (058110)?
The net margin of MEKICS Co Ltd is 3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEKICS Co Ltd (058110)?
The return on equity (ROE) of MEKICS Co Ltd is −2,189% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEKICS Co Ltd (058110)?
On an EBIT basis the return on assets of MEKICS Co Ltd is −6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEKICS Co Ltd (058110)?
The operating margin of MEKICS Co Ltd is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEKICS Co Ltd (058110)?
Revenue at MEKICS Co Ltd is down 56.3% versus a year earlier (3y avg −26.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEKICS Co Ltd (058110)?
Earnings per share at MEKICS Co Ltd are growing 4.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does MEKICS Co Ltd (058110) generate?
The free cash flow of MEKICS Co Ltd is −2.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MEKICS Co Ltd (058110) carry?
The net debt of MEKICS Co Ltd is 12.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MEKICS Co Ltd in the live analysis

One click puts MEKICS Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.